Colon Cancer Death Rates Are Falling Among the Young - But Only for Whites
Race and ethnicity matter when battling colon cancer, with young white patients facing notably better odds than Black, Hispanic or Asian patients, new research warns.
A look at colon cancer survival among Americans younger than 50 turned up a glaring discrepancy: Survival five years after diagnosis improved to nearly 70% among white patients over two decades, but was less than 58% among Black patients.
All had been diagnosed with early-stage disease, starting in 1992.
Moreover, the researchers found that the size of the survival gap grew over time. "Survival for Blacks diagnosed from 2003 to 2013 remained even lower than for whites diagnosed a decade earlier," noted study lead author Dr. Timothy Zaki.
Colon cancer is striking younger people around the world. A study published in May in the New England Journal of Medicine reported that 10% of colon cancer cases are now early-onset -- in patients younger than 50 -- and incidence is rising. As a result, screening is now recommended in the United States to start at age 45.
Prior research suggests these disparities in survival are not new, stressed Zaki, a resident physician at the University of Texas Southwestern Medical Center in Dallas.
Similar racial and ethnic survival rates gaps are also "well-documented" among colon cancer patients over age 50, said Zaki.
Moreover, previous investigations have indicated that young white patients face a notably lower risk of developing colon cancer in the first place, he noted.
Zaki suggested there is no obvious explanation for what is going on, an observation echoed by Dr. William Dahut, chief scientific officer of the American Cancer Society.
The disparity in survival is "not trivial," said Dahut, who was not involved with the study. However, "in this particular study, it is not possible to fully explain differences between Black patients and those of other racial or ethnic backgrounds," he said.
Still, both Zaki and Dahut pointed to a wide range of contributing issues.
Zaki highlighted potential ethnic and racial differences in employment, social support, family income, environmental exposure, education level, lifestyle choices (such as smoking, diet and drinking habits), culture and health insurance.
And Dahut noted the possibility that there are "differences in the biology of the tumor itself or in a predisposition to cancer that certain populations may have."
Differences in the number and types of preexisting medical conditions at the time of cancer diagnosis might also play a role, added Zaki, as may the speed with which patients access cancer treatment.
For the study, Zaki and his colleagues reviewed stats collected between 1992 and 2013 by the U.S. National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER).
The data covered about 30% of the U.S. population. Out of that pool, nearly 34,000 men and women between the ages of 20 and 49 were diagnosed with early-onset colon cancer.
About 6 in 10 were white, while nearly 15% were Hispanic, 14% were Black and 13% were Asian.
White patients were the most likely to be alive five years out, with a 69% survival rate. That was followed by 67% among Asian/Pacific Islanders and 63% among Hispanics. Survival approached just 58% among Black patients.
The worst survival rate was seen among Black men (less than 57%), while the highest survival rate was observed among white women (nearly 71%).
Even when looking solely at local-stage disease (caught before it spread), Black patients fared worse: Five-year survival exceeded 94% among whites but remained about 89% among Black people.
And in relative terms the situation didn't improve with time. Black people diagnosed during the second decade (2003-2013) of the study had a 59% survival rate, which was below the 66% survival rate seen for whites in the first decade (1992-2002) -- and well below the 70%-plus rate among whites during the second decade.
The findings were scheduled for presentation Tuesday at the American Gastroenterological Association's Digestive Disease Week meeting, in San Diego. Research presented at meetings is usually considered preliminary until published in a peer-reviewed medical journal.
The U.S. Centers for Disease Control and Prevention lists colon cancer risk factors.
SOURCES: Timothy Zaki, MD, internal medicine resident physician, University of Texas Southwestern Medical Center, Dallas; William L. Dahut, MD, chief scientific officer, American Cancer Society; American Gastroenterological Association, Digestive Disease Week meeting, San Diego, May 21-24, 2022